Eltrombopag Olamine

DRUG10 trials

Sponsors

GlaxoSmithKline, M.D. Anderson Cancer Center, Roswell Park Cancer Institute, Fondazione Progetto Ematologia, Albert Einstein College of Medicine

Conditions

Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAcute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic SyndromeAdult Acute Basophilic LeukemiaAdult Acute Eosinophilic LeukemiaAdult Acute Megakaryoblastic Leukemia (M7)Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monocytic Leukemia (M5b)

Phase 1

Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)

CompletedNCT00903422

GlaxoSmithKlineMyelodysplastic Syndrome

Start: 2009-05-14End: 2013-12-05Updated: 2017-11-13

Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia

TerminatedNCT01550185

Roswell Park Cancer InstituteAdult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia (M7) +14

Start: 2012-05-31End: 2014-12-31Updated: 2022-07-22

Phase 2

Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag

CompletedNCT01147809

GlaxoSmithKlineThrombocytopaenia

Start: 2010-06-30End: 2015-03-31Updated: 2016-04-18

Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase Therapy

CompletedNCT01428635

M.D. Anderson Cancer CenterAccelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive +2

Start: 2012-01-13End: 2022-01-03Updated: 2023-09-26

Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs)

CompletedNCT01610180

Fondazione Progetto EmatologiaAutoimmune Thrombocytopenia, Autoimmune Thrombocytopenic Purpura, Chronic Lymphocytic Leukemia +2

Start: 2012-06-30End: 2018-06-30Updated: 2018-07-16

Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic Anemia

CompletedNCT01772420

Albert Einstein College of MedicineAdult Myelodysplastic Syndrome, Anemia, Chronic Myelomonocytic Leukemia

Start: 2012-10-31End: 2020-07-09Updated: 2023-07-27

Eltrombopag Olamine in Increasing Platelet Counts in Patients Undergoing Transplant

CompletedNCT01927731

M.D. Anderson Cancer CenterBone Marrow Transplantation Recipient, Cord Blood Transplant Recipient, Hematopoietic Cell Transplantation Recipient

Start: 2013-10-14End: 2023-06-06Updated: 2024-04-23

Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy

CompletedNCT02071901

Case Comprehensive Cancer CenterAcute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia +16

Start: 2014-08-14End: 2019-01-06Updated: 2026-08-07

Eltrombopag for Peripheral Blood Stem Cell Harvest

RecruitingNCT05961410

National Taiwan University HospitalLymphoma, Peripheral Blood Stem Cell Transplantation

Start: 2023-08-15End: 2026-03-01Target: 46Updated: 2024-10-18

Phase 4

A Longitudinal 2-year Bone Marrow Study of Eltrombopag in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

CompletedNCT01098487

GlaxoSmithKlinePurpura, Thrombocytopaenic, Idiopathic

Start: 2010-05-31End: 2014-05-31Updated: 2015-03-12

Related Papers

Lenalidomide and Eltrombopag for Treatment of Low- or Intermediate-Risk Myelodysplastic Syndrome: Result of a Phase II Clinical Trial

Clinical Cancer Research2022-10-188 citations

Lenalidomide and Eltrombopag for Treatment in Low or Intermediate Risk Myelodysplastic Syndrome: Result of a Phase 2 Study Combination Clinical Trial

Blood2021-11-053 citations

The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis

Haematologica2020-09-1420 citations

A Single Arm, Phase II Study of Eltrombopag to Enhance Platelet Count Recovery in Older Patients with Acute Myeloid Leukemia (AML) Undergoing Remission Induction Therapy

Blood2019-11-132 citations

Eltrombopag for immune thrombocytopenia secondary to chronic lymphoproliferative disorders: a phase 2 multicenter study.

2019-11-0115 citations

The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis.

Journal of Clinical Oncology2019-05-205 citations

A Single Arm, Phase II Study of Eltrombopag to Enhance Platelet Count Recovery in Older Patients with Acute Myeloid Leukemia Undergoing Remission Induction Therapy

Blood2016-12-024 citations

Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial.

2015-10-0154 citations

Safety and efficacy of eltrombopag (EPAG) vs placebo (PBO) for treatment of chemotherapy (CTx)-induced thrombocytopenia (TCP) in patients (Pts) with solid tumors receiving gemcitabine (GEM)-based CTx: A phase 2 study.

Journal of Clinical Oncology2015-05-202 citations